ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Parkin is tyrosine phosphorylated in the N-terminal domain by c-Abl, and Imatinib, a specific c-Abl kinase inhibitor used for treating chronic myeloid leukemia and gastrointestinal stromal tumors, inhibits that tyrosine phosphorylation.